Fluzone Intradermal Quadrivalent (influenza vaccine) / Evotec, Sanofi - LARVOL DELTA

A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone® or Flublok®) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of age. (PubMed, Vaccine) - P1 | "In this highly immunologically-experienced cohort, neither AF03 nor Advax-CpG55.2 demonstrated notable benefit when added to the seasonal influenza vaccine. (ClinicalTrials.gov ID# NCT03945825)."

Clinical • Journal • P1 data • Infectious Disease • Influenza • Respiratory Diseases